Early introduction is not enough: CSACI statement on the importance of ongoing regular ingestion as a means of food allergy prevention.
Journal Information
Full Title: Allergy Asthma Clin Immunol
Abbreviation: Allergy Asthma Clin Immunol
Country: Unknown
Publisher: Unknown
Language: N/A
Publication Details
Related Papers from Same Journal
Transparency Score
Transparency Indicators
Click on green indicators to view evidence textCore Indicators
"Declarations Ethical approval consent to participate.Not applicable. Competing interestsEMA is an employee of Public Health Agency of Canada (PHAC); views expressed are her own and not those of PHAC. She is Section Head for Anaphylaxis/Food Allergy, and a Member of the Board, for the Canadian Society of Allergy and Clinical Immunology. JP is Section Head for Allied Health, and a Member of the Board, for the Canadian Society of Allergy and Clinical Immunology; sits on the steering committee for Canada’s National Food Allergy Action Plan, and reports consultancy for Nutricia, Novartis and ALK-Abelló.MBS has received consultant and/or speaker fees from Medexsus, Sanofi, Miravo, Stallergens and Novartis. EL has been a member of advisory boards for Pfizer, Miravo, Medexus, Stallergenes and ALK; has provided consultant services to ALK. ESC has received research support from DBV Technologies; has been a member of advisory boards for Pfizer, Miravo, Medexus, Leo Pharma, Kaleo, DBV, AllerGenis, Sanofi Genzyme, Bausch Health, Avir Pharma, AstraZeneca, ALK; was an expert panel and coordinating committee member of the National Institute of Allergy and Infectious Diseases (NIAID)-sponsored Guidelines for Peanut Allergy Prevention; is co-lead of CPS/CSACI Food Allergy Prevention Position Statements; is on the Executive of the CSACI (Canadian Society of Allergy and Clinical Immunology); is on the Executive of the CPS (Canadian Paediatric Society) Allergy Section; and is a member of the healthcare advisory board for Food Allergy Canada. Competing interests EMA is an employee of Public Health Agency of Canada (PHAC); views expressed are her own and not those of PHAC. She is Section Head for Anaphylaxis/Food Allergy, and a Member of the Board, for the Canadian Society of Allergy and Clinical Immunology. JP is Section Head for Allied Health, and a Member of the Board, for the Canadian Society of Allergy and Clinical Immunology; sits on the steering committee for Canada’s National Food Allergy Action Plan, and reports consultancy for Nutricia, Novartis and ALK-Abelló.MBS has received consultant and/or speaker fees from Medexsus, Sanofi, Miravo, Stallergens and Novartis. EL has been a member of advisory boards for Pfizer, Miravo, Medexus, Stallergenes and ALK; has provided consultant services to ALK. ESC has received research support from DBV Technologies; has been a member of advisory boards for Pfizer, Miravo, Medexus, Leo Pharma, Kaleo, DBV, AllerGenis, Sanofi Genzyme, Bausch Health, Avir Pharma, AstraZeneca, ALK; was an expert panel and coordinating committee member of the National Institute of Allergy and Infectious Diseases (NIAID)-sponsored Guidelines for Peanut Allergy Prevention; is co-lead of CPS/CSACI Food Allergy Prevention Position Statements; is on the Executive of the CSACI (Canadian Society of Allergy and Clinical Immunology); is on the Executive of the CPS (Canadian Paediatric Society) Allergy Section; and is a member of the healthcare advisory board for Food Allergy Canada."
"Funding Not applicable."
Additional Indicators
Assessment Info
Tool: rtransparent
OST Version: N/A
Last Updated: Aug 05, 2025